Antimicrobial susceptibility of Streptococcus pneumoniae in Kazakhstan | CMAC

Antimicrobial susceptibility of Streptococcus pneumoniae in Kazakhstan

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):187-192

​ Azyzov I.S., Lavrinenko A.V., Kolesnichenko S.I., Shambilova N.A., Ahaeva A.S.
10.36488/cmac.2019.2.187-192
Streptococcus pneumoniae antimicrobial resistance Kazakhstan
Section
Personal Experience
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2):187-192

Objective.

To study antimicrobial susceptibility of Streptococcus pneumoniae clinical isolates obtained from the patients with community-acquired pneumonia in the Central Kazakhstan.

Materials and Methods.

A total of 186 clinical strains of S. pneumoniae were obtained from the patients with respiratory tract infections in the Central Kazakhstan over the period of 2012–2017. Antimicrobial susceptibility was determined by disk-diffusion method. The isolation and identification of pathogens was performed by routine methods. Antimicrobial (oxacillin, vancomycin, clindamycin, azithromycin, chloramphenicol, tetracycline, rifampin, levofloxacin, linezolid, trimethoprim/sulfamethoxazole) susceptibility testing was performed and interpreted according to CLSI criteria (M100-24).

Results.

The resistance rates were the following: oxacillin – 4.2%, azithromycin – 12.4%, tetracycline – 71.1%, chloramphenicol – 7.8%, trimethoprim/sulfamethoxazole – 57.1%, rifampin – 5.6% and levofloxacin – 3.4%. There were no S. pneumoniae isolates resistant to linezolid or vancomycin.

Conclusions.

The amoxicillin is recommended as a drug of choice for antimicrobial therapy of pneumococcal respiratory tract infections.

Azyzov Ilya Sulejmanovich

Karaganda Medical University, Karaganda, Kazakhstan
Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Lavrinenko A.V.

Karaganda Medical University, Karaganda, Kazakhstan

Kolesnichenko S.I.

Karaganda Medical University, Karaganda, Kazakhstan

Shambilova N.A.

Karaganda Medical University, Karaganda, Kazakhstan

Ahaeva A.S.

Karaganda Medical University, Karaganda, Kazakhstan

  • 1. Marrie T.J., Tyrrell G.J., Majumdar S.R., Eurich D.T. Risk factors for pneumococcal endocarditis. Eur J Clin Microbiol Infect Dis. 2018;37:277-280. DOI: 10.1007/s10096-017-3128-z
  • 2. Cherian T., Mulholland E.K., Carlin J.B., et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bulletin of the World Health Organization. 2005. Available at: https://apps.who.int/iris/bitstream/handle/10665/72957/bulletin_2005_83%285%29_353-359.pdf?sequence=1&isAllowed=y.
  • 3. Birtanov E.A., Coj A.V., Aktaeva L.M., Tuleugalieva A.E., Abdikarimova D.A. The health and the activities of healthcare organizations of the population of the Republic of Kazakhstan in 2016. Astana, 2016. 356 c. Russian.
  • 4. The Government of the Republic of Kazakhstan decree “On approval of the list of diseases, prophylactic vaccinations are carried out against; the Rules for their implementation and groups of the population are planned for vaccinated” of December 30, 2009, No. 2295. Russian.
  • 5. Karibayeva I. K., Aimbetova G., Amireev S., et al. Assessment of the Pneumococcal Vaccination Programme in Mangistau Region, Kazakhstan. Ekologiya cheloveka. 2015;3:32-39. Russian.
  • 6. Bisenova N.M., Ergalieva A.S. Results of prospective analysis of the antibiotic susceptibility of Streptococcus pneumoniae strains isolated from patients with progressive respiratory infections. Klinicheskaja medicina Kazahstana. 2017;43(1):90. Russian.
  • 7. The Clinical Laboratory Standards Institute (CLSI) M100-ED28:2018 Performance Standards for Antimicrobial Susceptibility Testing. CLSI, под ред. M. Melvin P. Weinstein, 27th edition, CLSI, 2018. 296 c.
  • 8. Dvoretsky L.I., Danilina V.A. The clinical significance of resistant pneumococci. Infektsii i antimikrobnaya terapiya. 2004;6(4):126-133. (Дворецкий Л.И., Данилина В.А. Клиническое значение резистентных пневмококков. Инфекции и антимикробная терапия. 2004;6(4):126-133.)
  • 9. Chuchalin A.G., Sinopal’nikov A.I., Kozlov R.S., et al. Clinical guidelines on diagnosis, treatment and prevention of severe community-acquired pneumonia in adults. Available at: http://antimicrob.net/wp-content/uploads/2014-Tyazhelaya-vnebolnichnayapnevmoniya.pdf. Russian.
  • 10. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. EUCAST. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf Accessed December 12, 2018.
  • 11. Chuchalin A.G., Sinopal'nikov A.I., Kozlov R.S., Tjurin I.E., Rachina S.A. Community-acquired pneumonia in adults: practical recommendations on diagnostics, treatment and prevention. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2003;5(3):198-224. Russian.
  • 12. Cornick J.E., Bentley S.D. Streptococcus pneumoniae: The evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect. 2012;14 (7-8):573-83.
  • 13. Grosso M. Del, Iannelli F., Messina C., et al. Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J Clin Microbiol. 2002;40:774-778. DOI: 10.1128/JCM.40.3.774-778.2002
  • 14. Cherazard R., Epstein M., Doan Thien-Ly., Salim T., Bharti Sh. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Therapeutics. 2017;24:e361-e369. DOI: 10.1097/MJT.0000000000000551
  • 15. Mazzariol A., Koncan R., Vitali L.A., Cornaglia G. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. J Antimicrob Chemother. 2007;59:1171-1176. DOI: 10.1093/jac/dkm089
  • 16. Fritsche T.R., Sader H.S., Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagnostic Microbiol Infect Dis. 2008;61:86-95. DOI: 10.1016/j.diagmicrobio.2008.02.008
  • 17. WHO Report on Surveillance of Antibiotic Consumption. 2016 – 2018 Early implementatione. WHO, 2018. 127 p. Available at: www.who.int/medicines/areas/rational_use/who-amr-amcreport-20181109.pdf.
  • 18. Ihambaeva A.N., Mazhitov T.M., Aldijarova N.T., Djusembaeva N.K. Dynamics and structure of consumption of systemic antimicrobial drugs. Nejrohirurgija i nevrologija Kazahstana. 2016;45(4):14-17. Russian.
  • 19. Nakai H., Sato T., Uno T., et al. Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Infect Chemother. 2018;24:83-87. DOI: 10.1016/j.jiac.2017.08.009
  • 20. Shen G.H., Tsao T.C., Kao S.J., et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents. 2012;39:201-205. DOI: 10.1016/j.ijantimicag.2011.11.014
  • 21. Kozlov R.S., Sivaya O.V., Kretchikova O.I., Ivanchik N.V. and Study Group «PEHASus». Antimicrobial Resistance of Streptococcus pneumoniae in Russia over the 1999-2009: Results of Multicenter Prospective Study PEHASus. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2010;12(4):200-206. Russian.
  • 22. Conly J.M., Johnston B.L. Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact? Canadian J Infect Dis. 2002;13:13-16.
  • 23. Jacobs M.R., Good C.E., Windau A.R., et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agent Chemother. 2010;54:2716-2719. DOI: 10.1128/AAC.01797-09
  • 24. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis. 2001;32:1608-1614.
  • 25. Kozlov R.S., Sivaya O.V., Kretchikova O.I., et al. Antimicrobila Resistance of Streptococcus pneumoniae in Russia over 1999-2009: Results of Multicenter Prespective Study PEHASsus. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2010;12(4):329-341. Russian.
  • 26. Kuzmenkov A.Yu, Trushin I.V, Avramenko A.A., et al. AMRmap: an online platform for monitoring antibiotic resistance. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(2):84-90. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared